RBC Capital analyst Trung Huynh reiterated an Outperform rating and $1,250.00 price target on Eli Lilly (NYSE: LLY).The analyst comments ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Hot Comments

Goldman Sachs on Eli Lilly (LLY): 'see the stock weakness as an overreaction'May 4, 2026 9:27 AM Guggenheim on Cabaletta Bio (CABA): 'compelling evidence that CAR-T activity can be achieved without preconditioning'May 4, 2026 9:20 AM Bernstein: We're buyers of weakness in LLYMay 4, 2026 9:15 AM Eli Lilly (LLY) PT Raised to $1,400 at Barclays, 'A remarkably strong quarter...and LLY's only just getting started'May 4, 2026 8:58 AM Wolfe Research Defending Eli Lilly (LLY) Amid 1.53% Drop: 'Faers For Foundayo Are Unfounded'May 4, 2026 8:57 AM Why Eli Lilly stock is down 3% today: FDA adverse event data explainedMay 4, 2026 8:44 AM Form SCHEDULE 13G ELI LILLY & Co Filed by: VANGUARD CAPITAL MANAGEMENT LLCMay 1, 2026 11:53 AM Eli Lilly (LLY) PT Lowered to $1,133 at BofA SecuritiesMay 1, 2026 10:53 AM